ZETIA SUMMARY
ZETIA (ezetimibe) is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols.
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.
Monotherapy
ZETIA
®, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia.
Combination Therapy with HMG-CoA Reductase Inhibitors (Statins)
ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia.
Combination Therapy with Fenofibrate
ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in adult patients with mixed hyperlipidemia.
The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
The effect of ZETIA on cardiovascular morbidity and mortality has not been determined.
ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Zetia (Ezetimibe)
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo-
and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab
in subjects with hypercholesterolemia on background statin therapy. [2014] Low-density lipoprotein cholesterol (LDL-C) levels are significantly associated
with atherosclerotic cardiovascular disease (ASCVD) risk, and studies using
interventions that lower LDL-C levels have been shown to reduce the risk of ASCVD
events and mortality... This
study will also provide comparative efficacy, safety, and tolerability data
between evolocumab and ezetimibe when added to background atorvastatin therapy.
Simvastatin but not ezetimibe reduces sympathetic activity despite similar
reductions in cholesterol levels. [2014] The relationship between the sympatholytic effects of statins and their
lipid-lowering activity remains unclear. Ezetimibe lowers cholesterol, but its
sympatholytic activity is unknown...
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered
with extended-release niacin in hyperlipidemic patients. [2013] CONCLUSIONS: These results suggest that E/S+N improves lipoprotein particle
The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet
and inflammatory biomarkers in patients with metabolic syndrome. [2013] In a randomized, double-blind, crossover study of 15 aspirin-naive patients (mean
age 48.8 ± 10.2 years) with the metabolic syndrome, statin monotherapy
(simvastatin 40 mg daily) was compared to combination therapy (simvastatin 40 mg
and ezetimibe 10 mg daily) on biomarkers of inflammation and platelet activity...
A comparison of efficacy and safety of an ezetimibe/simvastatin combination
compared with other intensified lipid-lowering treatment strategies in diabetic
patients with symptomatic cardiovascular disease. [2013] The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to
ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to
simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in
subjects with cardiovascular disease (CVD) and diabetes was assessed...
Clinical Trials Related to Zetia (Ezetimibe)
Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe) [Completed]
The purpose of this study is to compare the effect on LDL cholesterol levels of converting
patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10
milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.
A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244) [Completed]
This study is a non-interventional (observational) study in Japan to confirm the safety and
efficacy of Zetia when administered alone or in combination with other lipid-lowering drugs
in daily medical practice throughout a 12-week period. It is being conducted as a
post-approval commitment, in accordance with the Ministry of Health, Labour and Welfare's
guideline on Good Post-marketing Study Practice.
Post-marketing surveys are not considered applicable clinical trials and thus the results of
this survey will not be posted at its conclusion. The results will be submitted to public
health officials as required by applicable national and international laws.
A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245) [Completed]
This study is a non-interventional (observational) study in Japan to confirm the safety and
efficacy of Zetia when administered alone or in combination with other lipid-lowering drugs
in daily medical practice throughout a 52-week period. It is being conducted as a
post-approval commitment, in accordance with the Ministry of Health, Labour and Welfare's
guideline on Good Post-marketing Study Practice.
Post-marketing surveys are not considered applicable clinical trials and thus the results of
this survey will not be posted at its conclusion. The results will be submitted to public
health officials as required by applicable national and international laws.
Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia [Completed]
Coadministration of drugs is common in the pharmacologic treatment of dyslipidemia, with
statins and ezetimibe generally constituting the medication of choice. By acting at
different levels, the combination of these drugs allows the therapeutic objective to be
achieved. However, it is not known how these drugs qualitatively affect the composition of
lipoprotein subfractions, which differ in size and atherogenic potential. The investigators
set out to evaluate this effect as well as their effects on inflammatory, oxidative stress
and endothelial function parameters.
Effect of Simvastatin and Ezetimibe on Lipid and Inflammation [Completed]
Ezetimibe specifically blocks the absorption of dietary and biliary cholesterol and plant
sterols. Synergism of ezetimibe-statin therapy on LDL-cholesterol has been demonstrated, but
data concerning the pleiotropic effects of this combination are controversial. We tested the
hypothesis that the combination of simvastatin and ezetimibe would induce improvement in
inflammatory status, as reflected by leukocyte count and CRP, IL-6 and TNF-a levels. This
open-label trial evaluated whether this combination results in a synergistic effect the
pro-inflammatory status of pre-diabetic subjects. Fifty pre-diabetic subjects were randomly
assigned to one of 2 groups, one receiving ezetimibe (10 mg/d), the other, simvastatin (20
mg/d) for 12 weeks, followed by an additional 12-week period of combined therapy.
Reports of Suspected Zetia (Ezetimibe) Side Effects
Myalgia (38),
Pain in Extremity (31),
Fatigue (27),
Arthralgia (25),
Asthenia (24),
Dyspnoea (22),
Constipation (21),
Nausea (21),
Drug Ineffective (20),
Back Pain (20), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Zetia has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| Zetia review by 60 year old male patient | | Rating |
Overall rating: | | |
Effectiveness: | | Considerably Effective |
Side effects: | | No Side Effects | | Treatment Info |
Condition / reason: | | high cholestrol |
Dosage & duration: | | 10mg/day taken ongoing for the period of ongoing |
Other conditions: | | knee osteoartritis |
Other drugs taken: | | glucosamine, multivitamins | | Reported Results |
Benefits: | | My target was to have the a cholestrol reduction from 240 to under 200. I did not want want to take statins because I am not comfortable with drugs that inhibit normal metabolic processes. Evolution is parsimonius, and inhibition of any enzyme is likely to be reflected as an adverse effect in a seemingly unrelated area. Also, I did not want to take red yeast rice, which basically is a non-phrmaceutical grade of a statin. I liked the physical mode of action of Zetia. Within 6 months of starting treatment, my total cholesterol was down from to 200 and my HDL went up from 45 to 58. |
Side effects: | | I did not experience any perceptible side effects. |
Comments: | | See treatment benefits above. I take my daily dose of Zetia shortly after having my breakfast. |
|
|
Page last updated: 2015-08-10
|